NorthStar Medical Radioisotopes has formed a strategic partnership with the University of Wisconsin (UW) School of Medicine and Public Health and its Initiative for Theranostics and Particle Therapy (ITPT).
The multiyear project furthers the goal of turning southern Wisconsin into a nuclear medicine hub for cancer research and infrastructure development, according to NorthStar. With several initiatives already underway, the company plans to conduct collaborative research, clinical and translational research, and contract research and drug development.
Key goals of the partnership include radiopharmaceutical drug development services using UW-Madison's advanced research infrastructure and scientific expertise, as well as nuclear medicine education and workforce development.
NorthStar produces copper-67 (Cu-67) and plans to be one of the first commercial-scale producers of noncarrier added actinium-225 (n.c.a. Ac-225). The company also provides radiopharmaceutical contract development and manufacturing organization (CDMO) services.
The firm hopes the agreement will create academic and real-world educational opportunities to help develop a skilled radiopharmaceutical workforce, it said.
